Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,284.10 +58.37 (+4.76%)

Streaming Delayed Price Updated: 10:08 AM EDT, Aug 19, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Absci (ABSI) Q2 2026 Earnings Call Transcript ↗

Today 9:52 EDT

Biotech extends runway to 2028 with $100M financing and Eli Lilly deal.

Via The Motley Fool

Topics Earnings

Eli Lilly, Novo Nordisk Battle It Out In Weight-Loss Pills Market ↗

Today 8:00 EDT

The weight-loss pills battle between Eli Lilly and Novo Nordisk could add to the projected $200 billion obesity market.

Via Investor's Business Daily

Netflix, Eli Lilly, Elanco Animal Health And More Stock On CNBC’s ‘Final Trades’ ↗

Today 7:46 EDT

Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.

Via Benzinga

Why Eli Lilly (LLY) Stock Is Up Today

August 18, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3% in the afternoon session after the company announced two deals, acquiri...

Via StockStory

Eli Lilly (NYSE:LLY) Shows a Strong Technical Breakout Setup ↗

August 12, 2026

Via Chartmill

Which Healthcare ETF Is the Better Buy: VanEck's Pharma PPH or State Street's Biotech XBI? ↗

August 18, 2026

PPH offers the income and stability of proven pharmaceutical leaders while XBI swings for the fences across 155 smaller biotech names.

Via The Motley Fool

Topics ETFs

PPH vs. IYH: Which Healthcare Fund Is the Better Buy? ↗

August 18, 2026

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Via The Motley Fool

Topics ETFs

U.S. Physical Therapy Names Nchacha Etta as Chief Financial Officer /www.snipeso ↗

August 18, 2026

Outpatient physical therapy operators regularly strengthen their executive leadership to support long-term operational scaling and strategic financial mana

Via Talk Markets

3 Absurdly Cheap Dividend Stocks to Buy for Under $100 Right Now ↗

August 18, 2026

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

Via The Motley Fool

If I Were in My 20s, I'd Buy This Unstoppable Vanguard ETF and Hold It Forever ↗

August 18, 2026

Investors can reap big rewards over the long term by betting on growth in their younger years.

Via The Motley Fool

Topics Artificial Intelligence ETFs Economy

Why Is Omniab Stock Rallying After Eli Lilly Deal? ↗

August 17, 2026

The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket

Via Benzinga

Wall Street Says the Stock Market's Return Will Crush the Long-Term Average in the Next Year ↗

August 17, 2026

The S&P 500 returned 9.5% annually over the past two decades. Wall Street expects much bigger gains in the next year.

Via The Motley Fool

Topics Stocks

1 of Wall Street’s Favorite Stocks on Our Watchlist and 2 We Find Risky

August 17, 2026

Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptic...

Via StockStory

2 GLP-1 Stocks That Could Double Your Money by 2031 ↗

August 16, 2026

They are fairly risky, but their potential upside is massive.

Via The Motley Fool

Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient ↗

August 15, 2026

The company's peers in the pharmaceutical industry should be worried.

Via The Motley Fool

GLP-1 Demand Is Soaring. 2 Stocks That Could Benefit From This (Hint: Not Eli Lilly or Novo Nordisk) ↗

August 14, 2026

They are way more than just GLP-1 stocks.

Via The Motley Fool

Topics Intellectual Property

Eli Lilly Just Scored Europe's First Weight Loss Pill Approval -- and the Growth Story Keeps Getting Bigger ↗

August 14, 2026

The U.K.'s health regulator just approved Eli Lilly's new weight-loss pill, a huge win for the drug maker.

Via The Motley Fool

Fidelity Healthcare ETF vs. iShares Pharma Fund: Which Wins? ↗

August 14, 2026

Fidelity's lower 0.08% fee and broader 338-stock portfolio contrast sharply with iShares' concentrated pharma play, which delivered 60% returns in one year.

Via The Motley Fool

Topics ETFs

Amphastar (AMPH) Q2 2026 Earnings Call Transcript ↗

August 13, 2026

New product launches drove 5% revenue growth and margin expansion.

Via The Motley Fool

Topics Earnings

Simplify's PINK or iShares' IYH: Which Healthcare ETF Should Long-Term Investors Choose Right Now? ↗

August 13, 2026

Active management and a charitable mission drive Simplify's 42% gain, but iShares offers lower costs and higher dividend income for conservative investors.

Via The Motley Fool

Topics ETFs

Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or Simplify's Actively Managed PINK? ↗

August 13, 2026

Fidelity's broad, low-cost index approach goes head-to-head with an actively managed, mission-driven healthcare fund.

Via The Motley Fool

Topics ETFs

Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity ↗

August 13, 2026

The stock continues to look unstoppable.

Via The Motley Fool

Is Novo Nordisk's Wegovy-Fueled Rebound Evaporating? ↗

August 13, 2026

It's yet another setback for the drugmaker.

Via The Motley Fool

IYH vs. FBT: Broad Healthcare ETF or Concentrated Biotech Play? ↗

August 13, 2026

FBT delivered 57.7% returns over one year but with nearly double the maximum drawdown. IYH offers lower costs and steadier performance for risk-averse investors.

Via The Motley Fool

Topics ETFs

Eli Lilly (LLY) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.

Via The Motley Fool

Topics Earnings

VanEck Pharmaceutical ETF vs. Invesco Biotech ETF: Which Fund Fits Your Investing Style? ↗

August 12, 2026

VanEck targets established pharma giants with lower costs and volatility, while Invesco pursues high-growth biotech companies. One delivered stronger returns; the other weathered downturns better.

Via The Motley Fool

Topics ETFs

Eli Lilly Escalates Retatrutide Fight, Reports 200-Plus Illegal Sellers to Authorities ↗

August 12, 2026

Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.

Via Benzinga

Topics Law Enforcement Lawsuit

1 Vanguard ETF That Outperforms the S&P 500 and Still Has Room to Run ↗

August 12, 2026

It has proven to be a market-beater in more years than not.

Via The Motley Fool

Topics ETFs Stocks

5 Revealing Analyst Questions From Eli Lilly’s Q2 Earnings Call

August 12, 2026

Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited grow...

Via StockStory

Topics Earnings

Better Buy: Eli Lilly vs. Novo Nordisk ↗

August 11, 2026

Novo Nordisk is playing catch-up in the GLP-1 race.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.